

Extended reference list on poliovaccines

- in alphabetic order according to name of first author

abstract	abstract	abstract	20	20	
				1	

Abbink F, Buisman AM, Doornbos G, Woldman J, Kimman TG, Conyn-van Spaendonck MA. Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion. *J Infect Dis.* 2005 Mar 15;191(6):990-9.

Abraham R, Minor P, Dunn G, Modlin JF, Ogra PL. Shedding of virulent poliovirus revertants during immunization with oral poliovirus vaccine after prior immunization with inactivated polio vaccine. *J Infect Dis.* 1993 Nov;168(5):1105-9.

Alexander LN, Seward JF, Santibanez TA, Pallansch MA, Kew OM, Prevots DR, Strebel PM, Cono J, Wharton M, Orenstein WA, Sutter RW. Vaccine policy changes and epidemiology of poliomyelitis in the United States. *JAMA.* 2004 Oct 13;292(14):1696-701.

Asturias EJ, Dueger EL, Omer SB, Melville A, Nates SV, Laassri M, Chumakov K, Halsey NA. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants. *J Infect Dis.* 2007 Sep 1;196(5):692-8.

Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N, Mason J, Middleton P, Mrukowicz J, O'Connell D, Oxman AD, Phillips B, Schünemann HJ, Edejer TT, Varonen H, Vist GE, Williams JW Jr, Zaza S; GRADE Working Group. Grading quality of evidence and strength of recommendations. *BMJ.* 2004 Jun 19;328(7454):1490.

Benn CS, Fisker AB, Rodrigues A, Ravn H, Sartono E, Whittle H, Yazdanbakhsh M, Aaby P. Sex-Differential Effect on Infant Mortality of Oral Polio Vaccine Administered with BCG at Birth in Guinea-Bissau. A Natural Experiment. *PLoS ONE* | www.plosone.org 1 December 2008 | Volume 3 | Issue 12 | e4056

Bhaskaram P, Nair KM, Hemalatha P, Murthy N, Nair P. Systemic and mucosal immune response to polio vaccination with additional dose in newborn period. *J Trop Pediatr.* 1997 Aug;43(4):232-4.

Borčić B, Dobrovsak-Sourek V, Kaić B, Ljubicić M. A comparative study of reactogenicity and immunogenicity of an oral and an inactivated polio vaccine. *Acta Med Croatica.* 1998;52(3):155-8.

Böttiger M. Polio immunity to killed vaccine: an 18-year follow-up. *Vaccine.* 1990 Oct;8(5):443-5.

Cameron JC, Walsh D, Finlayson AR, Boyd JH. Oral polio vaccine and intussusception: a data linkage study using records for vaccination and hospitalization. *Am J Epidemiol*. 2006 Mar 15;163(6):528-33.

Carlsson RM, Claesson BA, Fagerlund E, Knutsson N, Lundin C. Antibody persistence in five-year-old children who received a pentavalent combination vaccine in infancy. *Pediatr Infect Dis J*. 2002 Jun;21(6):535-41.

Centers for Disease Control and Prevention (CDC). Imported vaccine-associated paralytic poliomyelitis--United States, 2005. *MMWR Morb Mortal Wkly Rep*. 2006 Feb 3;55(4):97-9.

Certification of poliomyelitis eradication. *Wkly Epidemiol Rec*. 2002 Jul 5;77(27):221-3.

Certification of poliomyelitis eradication--Western Pacific Region, October 2000. *MMWR Morb Mortal Wkly Rep*. 2001 Jan 12;50(1):1-3.

Certification of poliomyelitis eradication--the Americas, 1994. *MMWR Morb Mortal Wkly Rep*. 1994 Oct 7;43(39):720-2.

Cuba IPV Study Collaborative Group. Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba. *N Engl J Med*. 2007 Apr 12;356(15):1536-44.

Da Villa G, Picciottol L, Riberat G, Bencivenga M, Cotugno M, Hartmann P. Effective antibody response in newborn babies living in Maldives to simultaneous vaccination against hepatitis B, poliomyelitis, diphtheria and tetanus. *Vaccine*, Vol. 13, No. 9, pp. 795-799, 1995.

Dayan GH, Thorley M, Yamamura Y, Rodríguez N, McLaughlin S, Torres LM, Seda A, Carbia M, Alexander LN, Caceres V, Pallansch MA. Serologic response to inactivated poliovirus vaccine: a randomized clinical trial comparing 2 vaccination schedules in Puerto Rico. *J Infect Dis*. 2007 Jan 1;195(1):12-20.

Deming MS, Jaiteh KO, Otten MW Jr, Flagg EW, Jallow M, Cham M, Brogan D, N'jie H. Epidemic poliomyelitis in The Gambia following the control of poliomyelitis as an endemic disease. II. Clinical efficacy of trivalent oral polio vaccine. *Am J Epidemiol*. 1992 Feb 15;135(4):393-408.

Dong DX, Hu XM, Liu WJ, Li JS, Jin YC, Tan SG, Chen TQ, Fu JZ, Niu BY, Yu HM, et al. Immunization of neonates with trivalent oral poliomyelitis vaccine (Sabin). *Bull World Health Organ*. 1986;64(6):853-60. (No summary).

Dong DX. Immunization with oral poliovirus vaccine in China. *Rev Infect Dis*. 1984 May-Jun;6 Suppl 2:S431.

Dömök I. Experiences associated with the use of live poliovirus vaccine in Hungary, 1959-1982. *Rev Infect Dis*. 1984 May-Jun;6 Suppl 2:S413-8.

el-Sayed N, el-Gamal Y, Abbassy AA, Seoud I, Salama M, Kandeel A, Hossny E, Shawky A, Hussein HA, Pallansch MA, van der Avoort HG, Burton AH, Sreevatsava M, Malankar P,

Wahdan MH, Sutter RW. Monovalent type 1 oral poliovirus vaccine in newborns. *N Engl J Med*. 2008 Oct 16;359(16):1655-65.

Faden H, Duffy L, Sun M, Shuff C. Long-term immunity to poliovirus in children immunized with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines. *J Infect Dis*. 1993 Aug;168(2):452-4.

Faden H, Modlin JF, Thoms ML, McBean AM, Ferdon MB, Ogra PL. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. *J Infect Dis*. 1990 Dec;162(6):1291-7.

Fine PE, Carneiro IA. Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative. *Am J Epidemiol*. 1999 Nov 15;150(10):1001-21.

Fortuin M, Maine N, Mendy M, Hall A, George M, Whittle H. Measles, polio and tetanus toxoid antibody levels in Gambian children aged 3 to 4 years following routine vaccination. *Trans R Soc Trop Med Hyg*. 1995 May-Jun;89(3):326-9.

Gelfand HM, Leblanc DR, Fox JP, Conwell DP. Studies on the development of natural immunity to poliomyelitis in Louisiana. II. Description and analysis of episodes of infection observed in study group households. *Am J Hyg*. 1957 May;65(3):367-85.

Griffiths UK, Botham L, Schoub BD. The cost-effectiveness of alternative polio immunization policies in South Africa. *Vaccine*. 2006 Jul 17;24(29-30):5670-8.

Grimprel E, von Sonnenburg F, Sanger R, Abitbol V, Wolter JM, Schuerman LM. Combined reduced-antigen-content diphtheria–tetanus–acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults. *Vaccine* 23 (2005) 3657–3667.

Gylca R, Gylca V, Benes O, Melnic A, Chicu V, Weisbecker C, Willems P, Kaufhold A. A new DTPa-HBV-IPV vaccine co-administered with Hib, compared to a commercially available DTPw-IPV/Hib vaccine co-administered with HBV, given at 6, 10 and 14 weeks following HBV at birth. *Vaccine*. 2000 Nov 22;19(7-8):825-33.

Halsey NA, Blatter M, Bader G, Thoms ML, Willingham FF, O'Donovan JC, Pakula L, Berut F, Reisinger KS, Meschievitz C. Inactivated poliovirus vaccine alone or sequential inactivated and oral poliovirus vaccine in two-, four- and six-month-old infants with combination *Haemophilus influenzae* type b/hepatitis B vaccine. *Pediatr Infect Dis J*. 1997 Jul;16(7):675-9.

Halsey N, Galazka A. The efficacy of DPT and oral poliomyelitis immunization schedules initiated from birth to 12 weeks of age. *Bull World Health Organ*. 1985;63(6):1151-69.

Heymann DL, Murphy K, Brigaud M, Aymard M, Tembon A, Maben GK. Oral poliovirus vaccine in tropical Africa: greater impact on incidence of paralytic disease than expected from coverage surveys and seroconversion rates. *Bull World Health Organ*. 1987;65(4):495-501.

Jain PK, Dutta AK, Nangia S, Khare S, Saili A. Seroconversion following killed polio vaccine in neonates. *Indian J Pediatr*. 1997 Jul-Aug;64(4):511-5.

John TJ, Pandian R, Gadomski A, Steinhoff M, John M, Ray M. Control of poliomyelitis by pulse immunisation in Vellore, India. *Br Med J (Clin Res Ed)*. 1983 Jan 1;286(6358):31-2.

Jenkins HE, Aylward RB, Gasasira A, Donnelly CA, Abanida EA, Koleosho-Adelekan T, Grassly NC. Effectiveness of immunization against paralytic poliomyelitis in Nigeria. *N Engl J Med*. 2008 Oct 16;359(16):1666-74.

John TJ. Immunisation against polioviruses in developing countries. *Rev Med Virol* 1993; 3: 149-160.

Kelley PW, Petruccelli BP, Stehr-Green P, Erickson RL, Mason CJ. The susceptibility of young adult Americans to vaccine-preventable infections. A national serosurvey of US Army recruits. *JAMA*. 1991 Nov 20;266(19):2724-9.

Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. *Annu Rev Microbiol*. 2005;59:587-635.

Khare S, Kumari S, Nagpal IS, Sharma D, Verghese T. Oral polio vaccination in infants: beneficial effect of additional dose at birth. *Indian J Pediatr*. 1993 Mar-Apr;60(2):275-81.

Khetsuriani N, Prevots DR, Quick L, Elder ME, Pallansch M, Kew O, Sutter RW. Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis. *J Infect Dis*. 2003 Dec 15;188(12):1845-52.

Kim-Farley RJ, Rutherford G, Lichfield P, Hsu ST, Orenstein WA, Schonberger LB, Bart KJ, Lui KJ, Lin CC. Outbreak of paralytic poliomyelitis, Taiwan. *Lancet*. 1984 Dec 8;2(8415):1322-4.

Kok PW, Leeuwenburg J, Tukei P, van Wezel AL, Kapsenberg JG, van Steenis G, Galazka A, Robertson SE, Robinson D. Serological and virological assessment of oral and inactivated poliovirus vaccines in a rural population in Kenya. *Bull World Health Organ*. 1992;70(1):93-103.

Lagos R, Kotloff K, Hoffenbach A, San Martin O, Abrego P, Ureta AM, Pines E, Blondeau C, Bailleux F, Levine MM. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants. *Pediatr Infect Dis J*. 1998 Apr;17(4):294-304.

Lagos R, Hoffenbach A, Scemama M, Dupuy M, Schodel F, Hessel L, Levine M. Lot-to-lot consistency of a combined hexavalent diphtheria-tetanus-acellular-pertussis, hepatitis B, Inactivated polio and haemophilus B conjugate vaccine, administered to healthy Chilean infants at two, four and six months of age. *Hum Vaccin*. 2005 May-Jun;1(3):112-7.

Lahrech MT, Caudrelier P. Immunological response of Moroccan children and newborns to oral poliovirus vaccine prepared on Vero cells. *Vaccine*. 1990 Aug;8(4):306-7.

- Langue J, Matisse N, Pacoret P, Undreiner F, Boisnard F, Soubeyrand B; Pentavac study group. Persistence of antibodies at 5-6 years of age for children who had received a primary series vaccination with a pentavalent whole-cell pertussis vaccine and a first booster with a pentavalent acellular pertussis vaccine: immunogenicity and tolerance of second booster with a tetravalent acellular vaccine at 5-6 years of age. *Vaccine*. 2004 Mar 29;22(11-12):1406-14.
- Lasch EE, Abed Y, Marcus O, Gerichter CB, Melnick JL. Combined live and inactivated poliovirus vaccine to control poliomyelitis in a developing country--five years after. *Dev Biol Stand*. 1986;65:137-43.
- Lin TY, Wang YH, Huang YC, Chiu CH, Lin PY, Chen CJ, Chavand P, Ortiz E. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine. *Int J Infect Dis*. 2007 Nov;11(6):488-95.
- Lin TY, Wang YH, Chang LY, Huang YC, Kao HT, Lin PY, Lu HK, Chavand P, Ortiz E. A fully liquid diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis--Haemophilus influenzae type b conjugate vaccine: immunogenicity and safety of primary vaccination in Taiwanese infants. *Int J Infect Dis*. 2007 Mar;11(2):129-36.
- Linder N, Handsher R, German B, Sirota L, Bachman M, Zinger S, Mendelson E, Barzilai A. Controlled trial of immune response of preterm infants to recombinant hepatitis B and inactivated poliovirus vaccines administered simultaneously shortly after birth. *Arch Dis Child Fetal Neonatal Ed*. 2000 Jul;83(1):F24-7.
- Lim FS, Han HH, Jacquet JM, Bock HL. Primary vaccination of infants against hepatitis B can be completed using a combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliomyelitis-Haemophilus influenzae type B vaccine. *Ann Acad Med Singapore*. 2007 Oct;36(10):801-6.
- Lu CY, Kao CL, Lee CY, Lee PI, Huang LM. Immunogenicity and fecal poliovirus excretion in sequential use of inactivated and oral poliovirus vaccines. *J Formos Med Assoc*. 2001 Aug;100(8):513-8.
- Mas Lago P, Ramon Bravo J, Andrus JK, Comellas MM, Galindo MA, de Quadros CA, Bell E. Lessons from Cuba: mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies. *Bull World Health Organ*. 1994;72(2):221-5.
- McBean AM, Thoms ML, Albrecht P, Cuthie JC, Bernier R. Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines. *Am J Epidemiol*. 1988 Sep;128(3):615-28.
- Meriste S, Lutsar I, Tamm E, Willems P. Safety and immunogenicity of a primary course and booster dose of a combined diphtheria, tetanus, acellular pertussis, hepatitis B and inactivated poliovirus vaccine. *Scand J Infect Dis*. 2006;38(5):350-6.
- Miller MA, Sutter RW, Strebel PM, Hadler SC. Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule. *JAMA*. 1996 Sep 25;276(12):967-71.

Modlin JF, Halsey NA, Thoms ML, Meschievitz CK, Patriarca PA. Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group. *J Infect Dis.* 1997 Feb;175 Suppl 1:S228-34.

Muridin AD, Barreto L, Plotkin S. Inactivated poliovirus vaccine: past and present experience. *Vaccine.* 1996 Jun;14(8):735-46.

Nirmal S, Cherian T, Samuel BU, Rajasingh J, Raghupathy P, John TJ. Immune response of infants to fractional doses of intradermally administered inactivated poliovirus vaccine. *Vaccine.* 1998 May-Jun;16(9-10):928-31.

Nishio O, Ishihara Y, Sakae K, Nonomura Y, Kuno A, Yasukawa S, Inoue H, Miyamura K, Kono R. The trend of acquired immunity with live poliovirus vaccine and the effect of revaccination: follow-up of vaccinees for ten years. *J Biol Stand.* 1984 Jan;12(1):1-10.

Ogra PL, Faden HS, Abraham R, Duffy LC, Sun M, Minor PD. Effect of prior immunity on the shedding of virulent revertant virus in feces after oral immunization with live attenuated poliovirus vaccines. *J Infect Dis.* 1991 Jul;164(1):191-4.

Onorato IM, Modlin JF, McBean AM, Thoms ML, Losonsky GA, Bernier RH. Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines. *J Infect Dis.* 1991 Jan;163(1):1-6.

Osei-Kwasi M, Afari EA, Mimura K, Obeng-Ansah I, Ampofo WK, Nkrumah FK. Randomized, controlled trial of trivalent oral poliovirus vaccine (Sabin) starting at birth in Ghana. *Bull World Health Organ.* 1995;73(1):41-6.

Parent du Châtelet I, Merchant AT, Fisher-Hoch S, Luby SP, Plotkin SA, Moatter T, Agboatwalla M, McCormick JB. Serological response and poliovirus excretion following different combined oral and inactivated poliovirus vaccines immunization schedules. *Vaccine.* 2003 Apr 2;21(15):1710-8.

Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. *Rev Infect Dis.* 1991 Sep-Oct;13(5):926-39.

Phua KB, Quak SH, Lim FS, Goh P, Teoh YL, Datta SK, Han HH, Bock HL. Immunogenicity, reactogenicity and safety of a diphtheria-tetanus-acellular pertussis-inactivated polio and Haemophilus influenzae type b vaccine in a placebo-controlled rotavirus vaccine study. *Ann Acad Med Singapore.* 2008 Jul;37(7):546-53.

Posey DL, Linkins RW, Oliveria MJ, Monteiro D, Patriarca PA. The effect of diarrhea on oral poliovirus vaccine failure in Brazil. *J Infect Dis.* 1997 Feb;175 Suppl 1:S258-63.

Prevots DR, Sutter RW, Strebel PM, Weibel RE, Cochi SL. Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1991. Implications for estimating the risk of vaccine-associated disease. *Arch Pediatr Adolesc Med.* 1994 May;148(5):479-85.

Rahman MM, Mahalanabis D, Alvarez JO, Wahed MA, Islam MA and Habte D. Effect of early vitamin A supplementation on cell-mediated immunity in infants younger than 6 mo. *Am J Clin Nutr* 1997;65:144-8.

Robertson SE, Traverso HP, Drucker JA, Rovira EZ, Fabre-Teste B, Sow A, N'Diaye M, Sy MT, Diouf F. Clinical efficacy of a new, enhanced-potency, inactivated poliovirus vaccine. *Lancet*. 1988 Apr 23;1(8591):897-9.

Sabin AB, Michaels RH, Zirping P, Krugman S, Warren J. Effect of oral poliovirus vaccine in newborn children. II. Intestinal resistance and antibody response at 6 months in children fed type I vaccine at birth. *Pediatrics*. 1963 Apr;31:641-50. (No summary).

Schatzmayer HG, Maurice Y, Fujita M, de Fillipis AM. Serological evaluation of poliomyelitis oral and inactivated vaccines in an urban low-income population at Rio de Janeiro, Brazil. *Vaccine*. 1986 Jun;4(2):111-3.

Simoes EA, Padmini B, Steinhoff MC, Jadhav M, John TJ. Antibody response of infants to two doses of inactivated poliovirus vaccine of enhanced potency. *Am J Dis Child*. 1985 Oct;139(10):977-80.

Strebel PM, Sutter RW, Cochi SL, Biellik RJ, Brink EW, Kew OM, Pallansch MA, Orenstein WA, Hinman AR. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. *Clin Infect Dis*. 1992 Feb;14(2):568-79.

Sutter RW, Suleiman AJ, Malankar PG, Mehta FR, Medany MA, Arif MA, Linkins RW, Pallansch MA, El-Bualy MS, Robertson SE. Sequential use of inactivated poliovirus vaccine followed by oral poliovirus vaccine in Oman. *J Infect Dis*. 1997 Feb;175 Suppl 1:S235-40.

Sutter RW, Patriarca PA, Suleiman AJ, Pallansch MA, Zell ER, Malankar PG, Brogan S, al-Ghassani AA, el-Bualy MS. Paralytic poliomyelitis in Oman: association between regional differences in attack rate and variations in antibody responses to oral poliovirus vaccine. *Int J Epidemiol*. 1993 Oct;22(5):936-44.

Sutter RW, Patriarca PA, Brogan S, Malankar PG, Pallansch MA, Kew OM, Bass AG, Cochi SL, Alexander JP, Hall DB, et al. Outbreak of paralytic poliomyelitis in Oman: evidence for widespread transmission among fully vaccinated children. *Lancet*. 1991 Sep 21;338(8769):715-20.

Swartz TA, Green MS, Handscher R, Sofer D, Cohen-Dar M, Shohat T, Habib S, Barak E, Dror Z, Somekh E, Peled-Leviathan T, Yulzari R, Libling A, Mendelson E, Shulman LM. Intestinal immunity following a combined enhanced inactivated polio vaccine/oral polio vaccine programme in Israel. *Vaccine*. 2008 Feb 20;26(8):1083-90.

Swartz TA, Handsher R, Manor Y, Stoeckel P, Barkay A, Mendelson E, Leventhal A. Immune response to an intercalated enhanced inactivated polio vaccine/oral polio vaccine programme in Israel: impact on the control of poliomyelitis. *Vaccine*. 1998 Dec;16(20):2090-5.

Swartz TA, Handsher R, Stoeckel P, Drucker J, Caudrelier P, Van Wezel AL, Cohen H, Salk D, Salk J. Immunologic memory induced at birth by immunization with inactivated polio vaccine in a reduced schedule. *Eur J Epidemiol.* 1989 Jun;5(2):143-5.

Swartz TA, Roumiantzeff M, Peyron L, Stopler T, Drucker J, Epstein I, Leitner L, Goldblum N. Use of a combined DTP-polio vaccine in a reduced schedule. *Dev Biol Stand.* 1986;65:159-66.

Taffs RE, Enterline JC, Rusmil K, Muhilal, Suwardi SS, Rustama D, Djatnika, Cobra C, Semba RD, Cohen N, Asher DM. Oral iodine supplementation does not reduce neutralizing antibody responses to oral poliovirus vaccine. *Bulletin of the World Health Organization,* 1999, 77 (6).

Thompson KM, Tebbens RJ. Retrospective cost-effectiveness analyses for polio vaccination in the United States. *Risk Anal.* 2006 Dec;26(6):1423-40.

Tucker AW, Isaacs D, Burgess M. Cost-effectiveness analysis of changing from live oral poliovirus vaccine to inactivated poliovirus vaccine in Australia. *Aust N Z J Public Health.* 2001 Oct;25(5):411-6. *Aust N Z J Public Health.* 2001 Oct;25(5):411-6.

Vidor E, Meschievitz C, Plotkin S. Fifteen years of experience with Vero-produced enhanced potency inactivated poliovirus vaccine. *Pediatr Infect Dis J.* 1997 Mar;16(3):312-22.

Viviani S, Mendy M, Jack AD, Hall AJ, Montesano R, Whittle HC. EPI vaccines-induced antibody prevalence in 8–9 year-olds in The Gambia. *Tropical Medicine and International Health* volume 9 no 10 pp 1044–1049, October 2004.

von Magnus H, Petersen I. Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark. *Rev Infect Dis.* 1984 May-Jun;6 Suppl 2:S471-4.

Weckx LY, Schmidt BJ, Herrmann AA, Miyasaki CH, Novo NF. Early immunization of neonates with trivalent oral poliovirus vaccine. *Bull World Health Organ.* 1992;70(1):85-91.

WHO Collaborative Study Group: Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. *J Infect Dis.* 1997 Feb;175 Suppl 1:S215-27. [No authors listed]

WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in the Gambia, Oman, and Thailand. *Bulletin of the World Health Organization,* 1996, 74 (3): 253-268.

Zaman K, Sack DA, Yunus M, Arifeen SE, Podder G, Azim T, Luby S, Breiman RF, Neuzil K, Datta SK, Delem A, Suryakiran PV, Bock HL; Bangladeshi Rotavirus Vaccine study group. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. *Vaccine.* 2009 Feb 25;27(9):1333-9.